This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Anthera Pharmaceuticals, Inc.
Drug Names(s): LY315920, S-5920, varespladib sodium
Description: A-001 is an intravenously administered inhibitor of secretory phospholipase A2 (sPLA2).
Deal Structure: In September 2006, Anthera announced that it entered into a license agreement with Eli Lilly and Shionogi under which Anthera has obtained worldwide (except for Japan) development and commercialization rights to an entire platform of clinical and preclinical inhibitors of phospholipase A2 (PLA2) developed by Lilly and Shionogi as part of their collaboration.
Pursuant to its license agreement with the companies, Anthera has an obligation to pay to each of Eli Lilly and Shionogi significant milestone and royalty payments based upon how it develops and commercializes certain sPLA2 inhibitors, including A-002 and A-001, and its achievement of certain significant corporate, clinical and financial events. For A-002, Anthera is required to pay up to $32.0 million upon achievement of certain approval and post-approval sales milestones. For A-001, the company is required to pay up to $3.0 million upon achievement of certain clinical development milestones and up to $25.0 million upon...See full deal structure in Biomedtracker
Partners: Shionogi & Co. Ltd. Eli Lilly & Company
Pink Sheet Keeping Track: A Quintet Of Novel Approvals
Additional information available to subscribers only: